Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621 PHASE3 COMPLETED Results posted

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	512
Start date	Fri Mar 18 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
• Fluticasone Propionate 250mcg / salmeterol 50mcg
• Double-dummy placebo
• Salbutamol as needed

Countries

Italy, South Africa, Ukraine, Germany, United States, Spain